SEC Form 4 FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSI Washington, D.C. 20549
Check this box if no longe Section 16. Form 4 or Fo obligations may continue	rm 5
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ECURITIES AND EXCHANGE COMMISSION	
Washington, D.C. 20549	

OMB APPROVAL					
OMB Number: 3235-0287					
Estimated average burden					
hours per response:	0.5				

1. Name and Address of Reporting Person [*] Goldberg Mark Alan	2. Issuer Name and Ticker or Trading Symbol <u>Blueprint Medicines Corp</u> [BPMC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION	3. Date of Earliest Transaction (Month/Day/Year) 06/19/2020	Officer (give title Other (specify below) below)					
45 SIDNEY STREET	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02139		X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) (Disposed Of (D) (Instr. 3, 4 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	06/19/2020		М		1,312	Α	(1)	1,312	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3A. Deemed Execution Date, if any (Month/Day/Year) 6. Date Exercisable and 8. Price of Derivative Security (Instr. 5) 9. Number of 1. Title of 3. Transaction 5. Number 7. Title and 10. 11. Nature 2. Conversion or Exercise Price of Derivative Security 7. Litle and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Derivative Security (Instr. 3) 4. Transaction Code (Instr. 8) Date (Month/Day/Year) Expiration Date (Month/Day/Year) Ownership Form: of Indirect Beneficial derivative of Derivative Securities Beneficially Direct (D) Securities Ownership Acquired (A) or Disposed Owned Following Reported or Indirect (I) (Instr. 4) (Instr. 4) of (D) (Instr. 3, 4 Transaction(s) (Instr. 4) and 5) Amount or Number Date Exercisable Expiration Date of Shares (A) (D) Code ν Title Restricted Commo (1) Stock Units 06/19/2020 (2) (2) 1,312 Μ 1,312 \$<mark>0</mark> 0 D Stock

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested.

/s/ Christopher Frankenfield, Attorney-in-Fact

06/23/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.